Timothy Hodges
Internal Medicine · Carmel, INNPI 1881618999
Payments from drug & device makers
Across 231 payments — averaging $38.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$6K
- AstraZeneca$439
- GSK$393
- Novo Nordisk$384
- Lilly USA, LLC$261
- Amgen$233
- plus $2K from 18 others
What the payments were for
- Consulting fees$4,50051%
- Travel & lodging$91310%
- Food & beverage$3,41939%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 13 | $5,615 |
| AstraZeneca | 27 | $439 |
| GSK | 23 | $393 |
| Novo Nordisk | 30 | $384 |
| Lilly USA, LLC | 20 | $261 |
| Amgen | 12 | $233 |
| Merck | 17 | $193 |
| Boehringer Ingelheim | 11 | $182 |
| Johnson & Johnson | 16 | $182 |
| AbbVie(2 entities) | 10 | $164 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $120 |
| Pfizer | 7 | $107 |
| Antares Pharma, Inc. | 6 | $93 |
| Astellas Pharma US Inc | 5 | $72 |
| Amarin Pharma, Inc. | 4 | $70 |
| Kowa Pharmaceuticals America, Inc. | 5 | $64 |
| Nalpropion Pharmaceuticals LLC | 3 | $61 |
| E.r. Squibb & Sons, L.L.C. | 5 | $61 |
| Sanofi-aventis U.S. LLC | 3 | $43 |
| Novartis | 2 | $36 |
| Currax Pharmaceuticals LLC | 2 | $24 |
| Shire North American Group Inc | 1 | $21 |
| Exact Sciences | 1 | $20 |
| Ironshore Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,851 in reported general payments places this provider in the 90th percentile of 1,747 internal medicine providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 19 | $19,507 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,299 |
| Cyclosporine | 13 | $2,014 |
| SynthroidLevothyroxine Sodium | 19 | $1,589 |
| Pantoprazole Sodium | 70 | $935 |
| Rosuvastatin Calcium | 100 | $852 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 19 | $549 |
| Omeprazole | 31 | $519 |
| Atorvastatin Calcium | 62 | $516 |
| Metformin Hcl | 28 | $396 |
| Levothyroxine Sodium | 39 | $393 |
| Losartan Potassium | 22 | $374 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 12 | $353 |
| Tamsulosin Hcl | 39 | $351 |
| Bupropion XlBupropion Hcl | 24 | $318 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $182 | $19,50719 claims |
| GSKBreo Ellipta | $393 | $4,29912 claims |
| AbbVieSynthroid | $164 | $1,58919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Carmel
- Brian UlmerCarmel$29K
- Robert BuynakValparaiso$24.2M
- Mohammed AllawNewburgh$3.6M
- Raj VuppalanchiIndianapolis$3.4M
- Phillip TothIndianapolis$3.2M
- George CornettFranklin$1.3M
- Ajita NarayanLafayette$951K
- Abhinav SinghGreenwood$738K
- Georgiann LinnemeierIndianapolis$692K
- Wa'el BakdashAnderson$625K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.